One of the overriding goals of the Brown Cancer Center is translational research. One way to achieve this is to provide a conduit for investigators studying particular molecular targets to conduct structure-based drug design. The Molecular Modeling Core Facility is an integral part of the COBRE which is used by all the COBRE investigators and many NIH funded investigators. It provides a natural entryway for structural biological approaches developed by COBRE scientists and through its close interaction with the NMR Center, biophysicists, molecular biologists, chemists, medicinal chemists, computer scientists, and biochemists. The overall goal of the Facility is rationalization, prediction, and design, i.e. the rationalization of experimental data, the prediction of new empirical experiments, and the structure-based drug design of new agents.
The aims of the Core are to: 1. provide equipment and expertise for a variety of modeling applications 2. facilitate structure-based drug design for drug discovery and drug development, including facilitating testing of targeted compounds. 3. provide a bridge between crystallography, NMR, medicinal chemistry, and other disciplines 4. provide a collaborative environment for the BCC 5. inform the Structural Biology Program of advances in the field, and to implement them 6. educate the Structural Biology Program and others on possible enhancements to their research 7. train students on

Public Health Relevance

The Modeling Core is directly involved in drug discovery. It enables almost any investigator to determine if their system is targetable and provides potential compounds for testing as chemical probes or new drugs. This adds a new direct route for translational research that otherwise would not be available to many investigators.

National Institute of Health (NIH)
National Institute of General Medical Sciences (NIGMS)
Center Core Grants (P30)
Project #
Application #
Study Section
Special Emphasis Panel (ZGM1-TWD-C (C3))
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Louisville
United States
Zip Code
Zhao, Guoping; Neely, Aaron M; Schwarzer, Christian et al. (2016) N-(3-oxo-acyl) homoserine lactone inhibits tumor growth independent of Bcl-2 proteins. Oncotarget 7:5924-42
Smith, Colin A; Ban, David; Pratihar, Supriya et al. (2016) Allosteric switch regulates protein-protein binding through collective motion. Proc Natl Acad Sci U S A 113:3269-74
Garbett, Nichola C; Brock, Guy N (2016) Differential scanning calorimetry as a complementary diagnostic tool for the evaluation of biological samples. Biochim Biophys Acta 1860:981-9
Waigel, Sabine; Rendon, Beatriz E; Lamont, Gwyneth et al. (2016) MIF inhibition reverts the gene expression profile of human melanoma cell line-induced MDSCs to normal monocytes. Genom Data 7:240-2
Yaddanapudi, Kavitha; Rendon, Beatriz E; Lamont, Gwyneth et al. (2016) MIF Is Necessary for Late-Stage Melanoma Patient MDSC Immune Suppression and Differentiation. Cancer Immunol Res 4:101-12
Sabo, T Michael; Trent, John O; Lee, Donghan (2015) Population shuffling between ground and high energy excited states. Protein Sci 24:1714-9
England, Christopher G; Miller, M Clarke; Kuttan, Ashani et al. (2015) Release kinetics of paclitaxel and cisplatin from two and three layered gold nanoparticles. Eur J Pharm Biopharm 92:120-9
Miller, M Clarke; Ohrenberg, Carl J; Kuttan, Ashani et al. (2015) Separation of Quadruplex Polymorphism in DNA Sequences by Reversed-Phase Chromatography. Curr Protoc Nucleic Acid Chem 61:17.7.1-18
Satpathy, Shuchismita R; Jala, Venkatakrishna R; Bodduluri, Sobha R et al. (2015) Crystalline silica-induced leukotriene B4-dependent inflammation promotes lung tumour growth. Nat Commun 6:7064
Andreeva, Kalina; Soliman, Maha M; Cooper, Nigel G F (2015) Regulatory networks in retinal ischemia-reperfusion injury. BMC Genet 16:43

Showing the most recent 10 out of 46 publications